Hematopoietic progenitor cell mobilization in mice by sustained delivery of granulocyte colony-stimulating factor.

The objective of these studies was to determine the effect of sustained delivery of growth factors (GFs) on hematopoietic progenitor cells (HPCs) in mice. In these studies, granulocyte colony-stimulating factor (G-CSF) was administered using the poloxamer-based matrix, ProGelz (PG) and G-CSF, and pharmacokinetics (PKs) and HPC mobilization was assessed. A single injection of G-CSF formulated in PG (17% poloxamer-407 and 5% hydroxypropyl methylcellulose [HPMC]) administered to BALB/c mice mobilized HPC significantly more rapidly to the spleen, but not the blood, than multiple injections of saline-formulated G-CSF. Two days after a single injection of PG G-CSF, the frequency of colony-forming unit-culture (CFU-c) in the spleen was increased 289-fold compared with an 8-fold increase after 2 days of twice-daily injections of saline-formulated G-CSF. Indeed, 4 days of twice-daily G-CSF injections were required to achieve the same level of HPC mobilization. In contrast, a similar mobilization of HPC to the blood was observed between PG and saline-formulated G-CSF. The mechanism for the accelerated and increased mobilization to the spleen by the PG-formulation of G-CSF is due, in part, to its increased bioavailability (>1.5-fold), T(max) (6-fold), and prolonged elimination (Tbeta) half-life (>3-fold) as compared with a saline formulation. In addition, we observed a more rapid trafficking of the PG G-CSF to the marrow, which could also facilitate mobilization.

[1]  R. Saccardi,et al.  Endogenous splenic colonies and megakaryopoiesis in methylcellulose treated irradiated mice , 1985, Experientia.

[2]  Y. Sugiyama,et al.  Renal Clearance of a Recombinant Granulocyte Colony-Stimulating Factor, Nartograstim, in Rats , 1995, Pharmaceutical Research.

[3]  D. Follmann,et al.  G‐CSF‐induced spleen size changes in peripheral blood progenitor cell donors , 2003, Transfusion.

[4]  R. Mosley,et al.  Delivery of Flt3 ligand (Flt3L) using a poloxamer-based formulation increases biological activity in mice , 2003, Bone Marrow Transplantation.

[5]  L. R. Hill,et al.  Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Kotsilkova,et al.  Influence of hydrogel structure on the processes of water penetration and drug release from mixed hydroxypropylmethyl cellulose/thermally pregelatinized waxy maize starch hydrophilic matrices. , 2001, International journal of pharmaceutics.

[7]  B. Lord,et al.  Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  J. Schwartz,et al.  The Effect of Formulation Composition and Dissolution Parameters on the Gel Strength of Controlled Release Hydrogel Tablets , 2001, Pharmaceutical development and technology.

[9]  S M Moghimi,et al.  Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. , 2000, Trends in biotechnology.

[10]  J. Crawford,et al.  Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Metcalf,et al.  Identification of a genetic locus modulating splenomegaly induced by granulocyte colony-stimulating factor in mice , 2000, Leukemia.

[12]  T. Ulich,et al.  A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. , 1999, Experimental hematology.

[13]  J. Talmadge,et al.  Endogenous interleukin-8 (IL-8) surge in granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization. , 1999, Blood.

[14]  F. Aversa,et al.  Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor , 1999, The Lancet.

[15]  I. Benet,et al.  Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation , 1998, Bone Marrow Transplantation.

[16]  K. Matsushima,et al.  Enhanced mobilization of hematopoietic progenitor cells by mouse MIP‐2 and granulocyte colony‐stimulating factor in mice , 1997, Journal of leukocyte biology.

[17]  C. Scott,et al.  Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. , 1997, Blood.

[18]  A. Banga,et al.  Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses. , 1997, Pharmaceutical development and technology.

[19]  R. Bhardwaj,et al.  Controlled‐release delivery system for the α‐MSH analog Melanotan‐I using poloxamer 407 , 1996 .

[20]  T. Tötterman,et al.  Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. , 1996, Bone marrow transplantation.

[21]  G. Matsuzaki,et al.  Kinetics of serum granulocyte-colony stimulating factor (G-CSF) concentration and G-CSF receptor expression during G-CSF treatment of cyclophosphamide-treated mice. , 1996, International journal of immunopharmacology.

[22]  M. Fukuda,et al.  Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts , 1996, Antimicrobial agents and chemotherapy.

[23]  A. Roberts,et al.  Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. , 1995, Blood.

[24]  R. Willemze,et al.  Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. , 1995, Blood.

[25]  D. F. Ward,et al.  Intravenous Pluronic F-127 in early burn wound treatment in rats. , 1993, Burns : journal of the International Society for Burn Injuries.

[26]  S. Davis,et al.  The polyoxyethylene/polyoxypropylene block co‐polymer Poloxamer‐407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow , 1992, FEBS letters.

[27]  W. Evans,et al.  Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. , 1992, Blood.

[28]  H. Tanaka,et al.  Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. , 1991, Cancer research.

[29]  H. Tanaka,et al.  Pharmacokinetics of recombinant human granulocyte colony-stimulating factor in the rat. Single and multiple dosing studies. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[30]  M. Morimoto,et al.  In vitro and in vivo hematopoietic effect of mutant human granulocyte colony-stimulating factor. , 1990, Blood.

[31]  T. Dexter,et al.  A comparison of hematopoiesis in normal and splenectomized mice treated with granulocyte colony-stimulating factor. , 1990, Blood.

[32]  George Morstyn,et al.  Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor , 1989 .

[33]  J. Talmadge,et al.  Protective, restorative, and therapeutic properties of recombinant colony-stimulating factors. , 1989, Blood.

[34]  S. Davis,et al.  Targeting of colloidal particles to the bone marrow. , 1987, Life sciences.

[35]  F. Okada,et al.  Enhancement of therapeutic effects of recombinant interleukin 2 on a transplantable rat fibrosarcoma by the use of a sustained release vehicle, pluronic gel. , 1987, Cancer research.

[36]  D. Boggs,et al.  Effect of methylcellulose injection on murine hematopoiesis. , 1977, The American journal of physiology.

[37]  I. R. Schmolka Artificial skin. I. Preparation and properties of pluronic F-127 gels for treatment of burns. , 1972, Journal of biomedical materials research.